Skip to main content

Company News

  • Shilpa Medicare Limited ties up with Dr. Reddys Laboratories Limited for production of Sputnik V vaccine

    Shilpa Biologicals Private Limited, SBPL, has entered into a 3 year DefInitive Agreement with Dr. Reddys Laboratories Limited, DRL, for production supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.

  • Dr. Reddys Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access toCOVID-19 Treatment in India

    Dr. Reddys Laboratories Ltd announced that it has entered into a royalty-free, non-exclusive voluntary  licensing agreement with  Eli Lilly and Company for the manufacture and commercialization of the drug, baricitinib,in India.

  • Dr. Reddys Laboratories announces the launch of Ertapenem for Injection in the U.S. Market

    Dr. Reddys Laboratories Ltd announced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA).

  • BioArctic receives patent in Japan for new antibodies targeting Alzheimers disease

    BioArctic AB announced today that the Japanese Patent Office (JPO) has allowed the company’s Japanese patent application 2017-083057 for novel antibodies that could be developed into a treatment for Alzheimers disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aβ) and are linked to the company’s project AD1503. BioArctic received a patent in Europe based on the same antibodies in January 2021.

  • Sun Pharma to Make Eli Lillys Baricitinib Drug in India

    Sun Pharma has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company Lilly for expanding access to Lillys drug, baricitinib in India. Sun Pharma will manufacture and distribute the drug in India.

  • Lilly accelerating baricitinibs availability in India

    Eli Lilly and Company announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic.

  • Accenture fast-tracks Mankind Pharma digital transformation with data-driven cloud platform

    Accenture is now working with Mankind Pharma, India’s 4th largest pharmaceutical manufacturing company as per as per IQVIA, to speed up its digital transformation to become an intelligent enterprise, improving business agility, performance, and operational efficiency.

  • Glenmark launches Ryaltris AZ at an affordable price in India

    Glenmark Pharmaceuticals Limited, a research-led, global integrated pharmaceutical company, announced the launch of Ryaltris - AZ Nasal Spray for the treatment of moderate to severe allergic rhinitis, in India. Glenmark being one of the leaders in respiratory segment, has been the first to launch the branded generic version at an affordable cost for the treatment of allergic rhinitis in India. This will provide patients a far more convenient, cost effective treatment option in the country.

  • Janssen seeks European approval of CAR-T Therapy Ciltacabtagene Autoleucel

    The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that they have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma.

  • Pfizer Acquires Amplyx Pharmaceuticals

    Pfizer Inc that it has acquired Amplyx Pharmaceuticals, Inc., a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyxs lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.

Subscribe to Company News